Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 77

Sort by

Sort Order Select

Journal Articles

NK Cells Contribute to Therapeutic Effects of Type I Interferons in Polycythaemia Vera

Sabine Muth, Johanna Lossa, Tina Schnöder, Joschka Bartneck, Federico Marini, Frederic Ries, Nora Sophia Lindhauer, Matthias Klein, Tobias Bopp, Hansjörg Schild, Florian H Heidel, Hans Christian Probst, Markus P. Radsak

Blood (2023) 142 (Supplement 1): 5766.

https://doi.org/10.1182/blood-2023-179094

Published: 2023

Journal Articles

ELN Criteria for Cytoreduction Start Identify Patients with Polycythemia Vera at Higher Thrombotic Risk

Blood (2023) 142 (Supplement 1): 4527.

https://doi.org/10.1182/blood-2023-181553

Published: 2023

Journal Articles

Early Generation Telomerase Deficient Mice to Investigate Clonal Hematopoiesis in Aging

Claudia Bruedigam, Amy H Porter, Jasmin Straube, Guidan Cheng, Florian H Heidel, Steven W Lane

Blood (2023) 142 (Supplement 1): 5598.

https://doi.org/10.1182/blood-2023-191246

Published: 2023

Journal Articles

Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Blood (2022) 140 (Supplement 1): 1790–1793.

https://doi.org/10.1182/blood-2022-157265

Published: 2022

Journal Articles

Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: The "RAMP” Multicenter Prospective Study

Blood (2022) 140 (Supplement 1): 9726–9728.

https://doi.org/10.1182/blood-2022-165303

Published: 2022

Journal Articles

Prediction of Resistance to Hydroxyurea Therapy in Patients with Polycythemia Vera: A Machine Learning Study (PV-AIM)

Srdan Verstovsek, Florian H. Heidel, Valerio De Stefano, Mike Zuurman, Kenneth Bryan, Armita Afsharinejad, Jean-Jacques Kiladjian

Blood (2022) 140 (Supplement 1): 6823–6825.

https://doi.org/10.1182/blood-2022-157268

Published: 2022

Journal Articles

Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)

Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Alessandra Iurlo, Valerio De Stefano, Marta Anna Sobas, Elisa Rumi, Elena Maria Elli, Francesca Lunghi, Mercedes Gasior Kabat, Beatriz Cuevas, Paola Guglielmelli, Massimiliano Bonifacio, Monia Marchetti, Alberto Alvarez-Larran, Laura Maria Fox, Marta Bellini, Rosa Daffini, Giulia Benevolo, Gonzalo Carreño, Andrea Patriarca, Haifa Kathrin Al-Ali, Marcio Andrade, Francesca Palandri, Claire Harrison, Maria Angeles Foncillas, Santiago Osorio, Steffen Koschmieder, Elena Magro, Jean-Jacques Kiladjian, Estefanía Bolaños, Florian H. Heidel, Keina Quiroz, Martin Griesshammer, Valentín García Gutiérrez, Alberto Marin Sanchez, Juan Carlos Hernandez Boluda, Emma Lopez Abadia, Giuseppe Carli, Miguel Sagüés, Rajko Kusec, Blanca Xicoy, Margarita Guenova, Begoña Navas, Anna Angona, Edyta Cichocka, Anna Masternak, Daniele Cattaneo, Cristina Bucelli, Silvia Betti, Oscar Borsani, Fabrizio Cavalca, Sara Carbonell, Natalia Curto-Garcia, Lina Benajiba, Alessandro Rambaldi, Alessandro M. Vannucchi

Blood (2022) 140 (Supplement 1): 6815–6818.

https://doi.org/10.1182/blood-2022-158902

Published: 2022

Journal Articles

Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study

Blood (2022) 140 (Supplement 1): 590–593.

https://doi.org/10.1182/blood-2022-158501

Published: 2022

Journal Articles

Diagnosis and Treatment of MPN in Real Life - Interim-Analysis of an Exploratory Chart Review on 960 ET and MF Patients in Germany

Andreas Schmidt, Christiane Bernhardt, Anette Fries, Kathleen Jentsch-Ulrich, Andreas Josting, Stephan Kreher, Marcel Reiser, H. Tilman Steinmetz, Hans Tesch, Bernhard Kaufmann, Uta Rager, Carl C. Crodel, Francesca Palandri, Florian H. Heidel

Blood (2022) 140 (Supplement 1): 9698–9699.

https://doi.org/10.1182/blood-2022-157980

Published: 2022

Journal Articles

Loss of Cell Fate Determinant LLGL1 Impairs Leukemia Development in Acute Myeloid Leukemia

Theresa Eifert, Tina M. M Schnoeder, Chen-Jen Hsu, Alicia L Becker, Qirui Zhang, Juliane Mohr, Stephanie Frey, Sebastian Scholl, Lars Bullinger, Steven W Lane, Florian H. Heidel

Blood (2022) 140 (Supplement 1): 8680–8681.

https://doi.org/10.1182/blood-2022-157247

Published: 2022

Journal Articles

Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 487–488.

https://doi.org/10.1182/blood-2022-168166

Published: 2022

Journal Articles

Pre-Clinical Investigation of a Novel Small Molecule Inhibitor Targeting YBX1 in AML

Tina M Schnoeder, Florian Perner, Ashok Kumar Jayavelu, Lianghao Mao, Qirui Zhang, Chen-Jen Hsu, Theresa Eifert, Uwe Grunwald, Peter Mertens, Dhanir Tailor, Akram Taherinasab, Theodore P. Braun, Sanjay Malhotra, Florian H. Heidel

Blood (2022) 140 (Supplement 1): 491–492.

https://doi.org/10.1182/blood-2022-157574

Published: 2022

Journal Articles

Clinicohematologic and Molecular Response of Essential Thrombocythemia Patients Treated with Pegylated Interferon-Alpha: A Multicenter Study on Behalf of the German Study Group-MPN (GSG-MPN)

Frank Stegelmann, Lino L. Teichmann, Florian H. Heidel, Carl C. Crodel, Thomas Ernst, Sebastian Kreil, Andreas Reiter, Sara Otten, Stefanie Schauer, Ruth-Miriam Körber, Kim Kricheldorf, Susanne Isfort, Hartmut Döhner, Tim H. Brümmendorf, Martin Griesshammer, Konstanze Döhner, Steffen Koschmieder

Blood (2022) 140 (Supplement 1): 6874–6876.

https://doi.org/10.1182/blood-2022-165034

Published: 2022

Journal Articles

Gaps in the Assessment and Monitoring of Cardiovascular Risk and Psychological Burden in Polycythemia Vera: Landmark 2.0, a Worldwide Health Survey

Blood (2022) 140 (Supplement 1): 12162–12164.

https://doi.org/10.1182/blood-2022-162516

Published: 2022

Journal Articles

Functional Role of Histone Variant macroH2A1 (H2AFY) in Acute Myeloid Leukemia (AML)

Chen-Jen Hsu, Tina M. M Schnoeder, Theresa Eifert, Qirui Zhang, Oliver Meers, David Corujo, Maximilian Lassi, Raffaele Teperino, Stefan Dimitrov, Holger Bierhoff, Björn von Eyss, Florian Perner, Marcus Buschbeck, Florian H. Heidel

Blood (2022) 140 (Supplement 1): 726–727.

https://doi.org/10.1182/blood-2022-157245

Published: 2022

Journal Articles

PLCG1 is required for AML1-ETO leukemia stem cell self-renewal

Blood (2022) 139 (7): 1080–1097.

https://doi.org/10.1182/blood.2021012778

Published: 2022

Includes: Supplemental data

Journal Articles

Genomic Landscape and Molecular Risk in Patients with Advanced Myelofibrosis Treated within the Multicenter Phase Ib/II MPNSG0212 (POMINC) Trial

Blood (2021) 138 (Supplement 1): 4637.

https://doi.org/10.1182/blood-2021-150361

Published: 2021

Journal Articles

Efficacy and Safety of Ruxolitinib in the Treatment of Elderly Patients with Policythemia Vera Resistant/Intolerant to Hydroxyurea

Blood (2021) 138 (Supplement 1): 2581.

https://doi.org/10.1182/blood-2021-149612

Published: 2021

Journal Articles

Peripheral Blasts Are Associated with Response to Ruxolitinib and Outcome in Patients with Chronic-Phase Myelofibrosis

Blood (2021) 138 (Supplement 1): 3624.

https://doi.org/10.1182/blood-2021-152420

Published: 2021

Journal Articles

Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-140001

Published: 2020

NARROW

NK Cells Contribute to Therapeutic Effects of Type I Interferons in Polycythaemia Vera

ELN Criteria for Cytoreduction Start Identify Patients with Polycythemia Vera at Higher Thrombotic Risk

Early Generation Telomerase Deficient Mice to Investigate Clonal Hematopoiesis in Aging

Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: The "RAMP” Multicenter Prospective Study

Prediction of Resistance to Hydroxyurea Therapy in Patients with Polycythemia Vera: A Machine Learning Study (PV-AIM)

Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)

Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study

Diagnosis and Treatment of MPN in Real Life - Interim-Analysis of an Exploratory Chart Review on 960 ET and MF Patients in Germany

Loss of Cell Fate Determinant LLGL1 Impairs Leukemia Development in Acute Myeloid Leukemia

Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia

Pre-Clinical Investigation of a Novel Small Molecule Inhibitor Targeting YBX1 in AML

Clinicohematologic and Molecular Response of Essential Thrombocythemia Patients Treated with Pegylated Interferon-Alpha: A Multicenter Study on Behalf of the German Study Group-MPN (GSG-MPN)

Gaps in the Assessment and Monitoring of Cardiovascular Risk and Psychological Burden in Polycythemia Vera: Landmark 2.0, a Worldwide Health Survey

Functional Role of Histone Variant macroH2A1 (H2AFY) in Acute Myeloid Leukemia (AML)

PLCG1 is required for AML1-ETO leukemia stem cell self-renewal

Genomic Landscape and Molecular Risk in Patients with Advanced Myelofibrosis Treated within the Multicenter Phase Ib/II MPNSG0212 (POMINC) Trial

Efficacy and Safety of Ruxolitinib in the Treatment of Elderly Patients with Policythemia Vera Resistant/Intolerant to Hydroxyurea

Peripheral Blasts Are Associated with Response to Ruxolitinib and Outcome in Patients with Chronic-Phase Myelofibrosis

Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only